It is a long path from the development of an active pharmaceutical ingredient in the lab to an effective drug – a process that takes several years. Campus companies are often involved in this process on behalf of the pharmaceutical and biotech industry or academic groups.
The company Experimental Pharmacology & Oncology Berlin-Buch (EPO) is a leader in preclinical cancer research in Germany. Worldwide, EPO offers customized and comprehensive service for the preclinical development of novel cancer drugs and is specialized in the development of individualized tumor models.
Eckert & Ziegler: Seed Implantation for Prostate Cancer Receives Reimbursement for Outpatient Care
Seed implantation for prostate cancer is now to be reimbursed as an outpatient treatment by public health insurances in Germany. This was decided by the Federal Joint Committee (G-BA) with effect from...more ...
Single Mouse Trials: mimicking clinical phase II trials in PDX models with manageable costs and efforts
The long and successful collaboration of EPO Berlin-Buch GmbH with the Charité University Hospital in Berlin recently led to the following publicationmore ...
Calling all young STEM talent
The 57th edition of the “Jugend forscht” competition will soon kick off under the theme “Lass Zukunft da.” The MDC is once again co-sponsoring the search for tomorrow’s scientists – this year to be he...more ...
GMP Biotech Summer School
Good Manufacturing Practice (GMP) Basic Course Biotechnology (English)more ...